SLRX
Salarius Pharmaceuticals, Inc.
Set alert
52-week range unavailable
- YTD
- +29.47%
- 1 year
- -96.73%
- Open
- 0.706
- Prev close
- 0.84
- Mkt cap
- 2.26M
- Vol
- 5.96M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6865
- High
- 0.8976
- Forward P/E
- -0.17
- Beta
- 0.93
- Short ratio
- 0.08
- Inst. own
- 0.36%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.52
- 200-d avg
- 2.59
- 1y target
- 0.00
Key statistics
- Market cap
- 2.26M
- Enterprise value
- -1.26M
- Trailing P/E
- 0.00
- Forward P/E
- -0.17
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.15
- EPS (TTM)
- -5.14
- Beta
- 0.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.13M
- Total cash
- 3.27M
- Total debt
- 0
- Return on equity
- -119.83%
- Shares outstanding
- 1.44M
- Short % of float
- 4.55%
- 50-day average
- 1.52
- 200-day average
- 2.59
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.76 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | -53.60 | -2.37 | +51.23 | +95.58% |
| May 13, 2024 | Mar 1, 2024 | -53.60 | -3.28 | +50.32 | +93.88% |
| Mar 22, 2024 | Dec 1, 2023 | -8.08 | -1.76 | +6.32 | +78.22% |
| Nov 9, 2023 | Sep 1, 2023 | -8.56 | -5.20 | +3.36 | +39.25% |
| Aug 10, 2023 | Jun 1, 2023 | -10.08 | -11.44 | -1.36 | -13.49% |
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- salariuspharma.com
News
- Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Expands By 20.9%
- Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Down 2.6% – Should You Sell?
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
- Comparing NRx Pharmaceuticals (NASDAQ:NRXP) & Salarius Pharmaceuticals (NASDAQ:SLRX)
- Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
- Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Your note
Sign in to keep a note on SLRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARTHUR DAVID J | Chief Executive Officer | Stock Award(Grant) | Feb 12, 2023 | 49,135 |
| BURLESON TESS | Director | Stock Award(Grant) | Jan 2, 2023 | 2,722 |
| HANISH ARNOLD C | Director | Stock Award(Grant) | Jan 2, 2023 | 3,294 |
| LAMMERS PAUL I | Director | Stock Award(Grant) | Jan 2, 2023 | 1,718 |
| LIEBER JONATHAN I | Director | Stock Award(Grant) | Jan 2, 2023 | 2,940 |
| MCCREEDY BRUCE J JR | Director | Stock Award(Grant) | Jan 2, 2023 | 1,788 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.22% | 3,189 | 5.01K | Sep 29, 2024 |
| Citigroup Inc. | 0.11% | 1,610 | 2.53K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 260 | 408 | Sep 29, 2024 |
| Osaic Holdings Inc | 0.01% | 162 | 254 | Sep 29, 2024 |
| Blackrock Inc. | 0.00% | 1 | 1 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 18 | 28 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.40% | 5,738 | 9.01K | Oct 30, 2024 |
| Listed Funds Tr-Horizon Kinetics Medical ETF | 0.26% | 3,723 | 5.84K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.15% | 2,138 | 3.36K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.13% | 1,820 | 2.86K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.02% | 321 | 503 | Oct 30, 2024 |